What Is an Angiotensin Converting Enzyme Inhibitor?
2003; Lippincott Williams & Wilkins; Volume: 108; Issue: 3 Linguagem: Inglês
10.1161/01.cir.0000075957.16003.07
ISSN1524-4539
Autores Tópico(s)Hormonal Regulation and Hypertension
ResumoHomeCirculationVol. 108, No. 3What Is an Angiotensin Converting Enzyme Inhibitor? Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBWhat Is an Angiotensin Converting Enzyme Inhibitor? Nancy K. Sweitzer, MD, PhD Nancy K. SweitzerNancy K. Sweitzer From the Heart Failure Program, University of Wisconsin Hospital and Clinics, Madison, Wis. Originally published22 Jul 2003https://doi.org/10.1161/01.CIR.0000075957.16003.07Circulation. 2003;108:e16–e18Angiotensin converting enzyme inhibitors (ACE inhibitors) are drugs that block the body's production of angiotensin II. Angiotensin II is a hormone that circulates in the blood and has many effects on the cardiovascular system; its main role is to constrict blood vessels. This constriction can cause high blood pressure and increase the work required for the heart to pump blood into the body's main arteries. This causes a problem for the heart muscle if it has been weakened by a heart attack or heart failure. Blocking production of angiotensin II with ACE inhibitors prevents constriction of blood vessels, lowers blood pressure, and lessens the energy the heart has to expend from beat to beat.In many cardiovascular diseases, angiotensin II is present in abnormally high quantities. The importance of decreasing the damage caused by high levels of angiotensin II is increasingly recognized. ACE inhibitors available in the United States and their associated costs are listed in the Table. The generic names of all ACE inhibitors end with the letters "P-R-I-L" (all drugs have a generic name but may not be available for purchase in a generic form). Available ACE InhibitorsGeneric NameTrade Names (Manufacturer)Avail in Generic FormApproximate Cost for a Month's SupplyBenazeprilLotensin (Novartis)no$30CaptoprilCapoten (Bristol-Myers Squibb)yes$13EnalaprilVasotec (Merck)yes$11FosinoprilMonopril (Bristol-Myers Squibb)no$66LisinoprilPrinivil (Merck), Zestril (Zeneca)yes$20MoexiprilUnivasc (Schwarz Pharmaceuticals)no$27PerindoprilAceon (Solvay Pharmaceuticals)no$43QuinaprilAccupril (Pfizer)no$32RamiprilAltace (Monarch Pharmaceuticals)no$80TrandolaprilMavik (Knoll Pharmaceuticals)no$30In addition to the role it plays in constricting arteries and raising blood pressure, angiotensin II is also "growth-promoting" in a negative way, in that it causes increases in size or thickness of several cardiovascular structures. High levels of circulating angiotensin II lead to thickening of the heart, a condition known as hypertrophy. Hypertrophy of the heart has long been recognized as a marker for high risk of death caused by heart disease. In the presence of high levels of angiotensin II, the walls of blood vessels also become thicker and stiffer, in addition to constricting, and this is thought to predispose to cholesterol deposits and blockages in the arteries, which can lead to heart attacks and strokes. ACE inhibitors are prescribed to prevent or reverse the hypertrophy of the heart and vessel walls. The Figure illustrates the effects of angiotensin II and ACE inhibitors on the cardiovascular system. Download figureDownload PowerPointEffects of angiotensin II on the blood vessels and heart.Who Should Be Taking an ACE Inhibitor?Because of their ability to relax constricted blood vessels, ACE inhibitors were first used to lower blood pressure in people with high blood pressure (hypertension). However, there are many other equally effective agents available to lower blood pressure. Once these drugs had been developed, exciting new possibilities for therapy with ACE inhibitors were recognized. People with weakened heart muscles causing a condition known as heart failure have very high levels of angiotensin II in their blood. It has been established that giving people with heart failure ACE inhibitors delays the onset of symptoms, prevents death from heart failure, and lessens the frequency of hospitalizations. Use of ACE inhibitors was also investigated in people who had had heart attacks but who did not yet have symptoms of heart failure. Again, ACE inhibitors were shown to prevent deaths caused by heart disease in this group. A recent study looked at patients at high risk for having heart attacks or developing heart failure (people with known blockages in arteries, diabetes, or hypertension) and found that treatment with an ACE inhibitor prevented future heart attacks and deaths from heart disease in these groups of people. ACE inhibitors seem to be particularly effective drugs for reducing heart attacks in patients with diabetes. These drugs can also protect kidney function in patients with diabetes and patients with other forms of mild kidney disease, especially those with protein in the urine.Who Should Be Taking an ACE Inhibitor?Patients with: Heart failure (weakened heart muscle)Coronary artery disease (previous heart attack or angina)Adult onset diabetes"Diabetic tendency" and high blood pressureMild kidney disease, particularly if there is protein in the urineAre ACE Inhibitors Safe?ACE inhibitors are taken by thousands of patients and have been shown to be very safe. However, all medications have side effects, and there are some for which patients should be monitored. Because ACE inhibitors can lower blood pressure, lightheadedness and dizziness may result if blood pressure becomes too low. As ACE inhibitors reduce blood pressure only modestly in most patients, this is not a major problem, particularly if the initial dose is low. Oddly enough, the major side effect of ACE inhibitors is a cough. The cough occurs in about 15% of patients; however, it is mild in half of these patients and does not require stoppage of the drug. About 8% of patients have a cough bothersome enough that ACE inhibitor therapy has to be discontinued. Finally, ACE inhibitors can worsen kidney function in some patients, particularly if cholesterol buildup is blocking the arteries to both kidneys. However, long-term therapy with ACE inhibitors has been shown to prevent worsening of kidney function in patients with mild kidney disease due to diabetes or high blood pressure. If you have abnormal kidney function, ask your doctor for more information.Are There People Who Should Not Take ACE Inhibitors?About 1 in 100 patients have a severe throat and tongue swelling reaction called angioedema as a result of their first dose of an ACE inhibitor. Once this reaction occurs, ACE inhibitors should never be used again. Any person who has ever had a swelling reaction like this in any situation, such as after a bee sting or eating nuts, should avoid all ACE inhibitors.Because they have been associated with birth defects, ACE inhibitors are not safe during pregnancy. If you have cardiovascular disease treated with an ACE inhibitor and are or are thinking about becoming pregnant, contact your doctor immediately. These drugs are also not advised for use by nursing mothers.Will an ACE Inhibitor Interact With My Other Medications?ACE inhibitors are very safe and can be used in combination with almost any other medication. Other drugs that affect the kidneys, such as furosemide (Lasix) or hydrochlorothiazide should be used with caution, and kidney function should be monitored. In patients taking insulin, starting an ACE inhibitor may be associated with a fall in blood sugar to low levels, and sugars should be watched closely the first few days on the drug. Finally, some over-the-counter pain medication such as ibuprofen (for example, Advil, Motrin), naprosyn (Aleve), and other related compounds can make ACE inhibitors less effective and should be avoided. Acetaminophen (Tylenol) can be taken with ACE inhibitors. Review your medication use, including over-the-counter medications, with your doctor before beginning to take ACE inhibitors.FootnotesCorrespondence to Nancy K. Sweitzer, MD, PhD, University of Wisconsin Hospital and Clinics, E5/582 CSC Mail Code 5710, 600 Highland Ave, Madison, WI 53792. E-mail [email protected]Additional Resources Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician. 2002; 66: 461–468.MedlineGoogle ScholarNational Library of Medicine. MEDLINE plus health information. Available at: http://www.nlm.nih.gov/medlineplus./ Accessed June 23, 2003.Google ScholarWebMDHealth web site. Available at: http://my.webmd.com. Accessed June 23, 2003.Google ScholarNational Library of Medicine. Health information. Available at: http://www.nlm.nih.gov/hinfo.html. Accessed June 23, 2003.Google ScholarNational Institute of Diabetes and Digestive and Kidney Disease web site. Available at: http://www.niddk.nih.gov. Accessed June 23, 2003.Google ScholarCardio Info Innovations. Cardiology patient info. Available at: http://cardio-info.com/lnkpinfo.htm. Accessed June 23, 2003.Google ScholarCHFpatients.com web site. Available at: http://www.chfpatients.com. Accessed June 23, 2003.Google ScholarHeart Failure Society of America. Heart failure information and education. Available at: http://www.abouthf.org. Accessed June 23, 2003.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Abiad M, Ajjour C, Kassaify Z, Iskandar C, Hamzeh R and Hassan H (2022) Preliminary physiological, phenotypic, and probiotic characterization of Lactobacillus strains isolated from Anbaris-traditional Lebanese fermented dairy product , International Journal of Food Properties, 10.1080/10942912.2022.2077363, 25:1, (1266-1278), Online publication date: 31-Dec-2022. Karahan F and Turkoglu V (2021) Enhanced purification protocol for the angiotensin-converting enzyme from bovine systems and investigation of the in vitro effect of some active substances, Chemico-Biological Interactions, 10.1016/j.cbi.2021.109604, 347, (109604), Online publication date: 1-Sep-2021. Vieira C, Rosario A, Lelis C, Rekowsky B, Carvalho A, Rosário D, Elias T, Costa M, Foguel D, Conte-Junior C and Kouretas D (2021) Bioactive Compounds from Kefir and Their Potential Benefits on Health: A Systematic Review and Meta-Analysis, Oxidative Medicine and Cellular Longevity, 10.1155/2021/9081738, 2021, (1-34), Online publication date: 27-Oct-2021. Fujimura Y, Shimura M, Nagai H and Hamada-Sato N (2021) Evaluation of angiotensin-converting enzyme-inhibitory activity in abalone viscera fermented by Lactobacillus casei 001, Journal of Functional Foods, 10.1016/j.jff.2021.104474, 82, (104474), Online publication date: 1-Jul-2021. Amere Subbarao S (2021) Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting, Inflammopharmacology, 10.1007/s10787-021-00796-w, 29:2, (343-366), Online publication date: 1-Apr-2021. Chai K, Voo A and Chen W (2020) Bioactive peptides from food fermentation: A comprehensive review of their sources, bioactivities, applications, and future development, Comprehensive Reviews in Food Science and Food Safety, 10.1111/1541-4337.12651, 19:6, (3825-3885), Online publication date: 1-Nov-2020. Kumagai Y, Kitade Y, Kobayashi M, Watanabe K, Kurita H, Takeda H, Yasui H and Kishimura H (2020) Identification of ACE inhibitory peptides from red alga Mazzaella japonica, European Food Research and Technology, 10.1007/s00217-020-03567-z, 246:11, (2225-2231), Online publication date: 1-Nov-2020. Park H, Kim J, Kim H, Lee S, Jang J and Lee M (2018) Synergistic effect of fruit–seed mixed juice on inhibition of angiotensin I-converting enzyme and activation of NO production in EA.hy926 cells, Food Science and Biotechnology, 10.1007/s10068-018-0512-0, 28:3, (881-893), Online publication date: 1-Jun-2019. Sikanyika N, Parkington H, Smith A and Kuruppu S (2019) Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease, Neurochemical Research, 10.1007/s11064-019-02756-x, 44:6, (1289-1296), Online publication date: 1-Jun-2019. Peña B, Laughter M, Jett S, Rowland T, Taylor M, Mestroni L and Park D (2018) Injectable Hydrogels for Cardiac Tissue Engineering, Macromolecular Bioscience, 10.1002/mabi.201800079, 18:6, (1800079), Online publication date: 1-Jun-2018. Nagaratnam N, Nagaratnam K and Cheuk G (2018) Heart Failure Geriatric Diseases, 10.1007/978-3-319-33434-9_1, (3-16), . Tao M, Wang C, Liao D, Liu H, Zhao Z and Zhao Z (2017) Purification, modification and inhibition mechanism of angiotensin I-converting enzyme inhibitory peptide from silkworm pupa (Bombyx mori) protein hydrolysate, Process Biochemistry, 10.1016/j.procbio.2016.12.022, 54, (172-179), Online publication date: 1-Mar-2017. Kovarik J, Kopecky C, Antlanger M, Domenig O, Kaltenecker C, Werzowa J, Hecking M, Mahr S, Grömmer M, Wallner C, Aumayr K, Kain R, Zuckermann A, Poglitsch M and Säemann M (2017) Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients, The Journal of Heart and Lung Transplantation, 10.1016/j.healun.2016.08.022, 36:3, (355-365), Online publication date: 1-Mar-2017. Ray S, Dutta M, Chaudhury K and De B (2017) GC–MS based metabolite profiling and angiotensin I-converting enzyme inhibitory property of black tea extracts, Revista Brasileira de Farmacognosia, 10.1016/j.bjp.2017.05.006, 27:5, (580-586), Online publication date: 1-Sep-2017. Nizami H and Banerjee S (2017) Mechanisms of Action of Drugs for Treating Endothelial Dysfunction in Diabetes Mellitus Mechanisms of Vascular Defects in Diabetes Mellitus, 10.1007/978-3-319-60324-7_22, (483-514), . Au A, Cheng K and Wei L (2016) Metabolomics, Lipidomics and Pharmacometabolomics of Human Hypertension Hypertension: from basic research to clinical practice, 10.1007/5584_2016_79, (599-613), . Nagaratnam N, Nagaratnam K and Cheuk G (2017) Heart Failure Geriatric Diseases, 10.1007/978-3-319-32700-6_1-1, (1-13), . Al-Qattan K, Thomson M and Ali M (2017) Garlic extract increases non-clipped kidney tubular natriuresis and diuresis in the 2-kidney, 1-clip rat model: Significance in hypertension, Pathophysiology, 10.1016/j.pathophys.2017.08.004, 24:4, (317-325), Online publication date: 1-Dec-2017. Acharya J, Karak S and De B (2016) Metabolite Profile and Bioactivity of Musa X Paradisiaca L. Flower Extracts , Journal of Food Biochemistry, 10.1111/jfbc.12263, 40:6, (724-730), Online publication date: 1-Dec-2016. Visvanathan R, Jayathilake C, Chaminda Jayawardana B and Liyanage R (2016) Health-beneficial properties of potato and compounds of interest, Journal of the Science of Food and Agriculture, 10.1002/jsfa.7848, 96:15, (4850-4860), Online publication date: 1-Dec-2016. Mirowsky J and Ross C (2015) Education, Health, and the Default American Lifestyle, Journal of Health and Social Behavior, 10.1177/0022146515594814, 56:3, (297-306), Online publication date: 1-Sep-2015. Tham Y, Bernardo B, Ooi J, Weeks K and McMullen J (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets, Archives of Toxicology, 10.1007/s00204-015-1477-x, 89:9, (1401-1438), Online publication date: 1-Sep-2015. Iwaniak A, Minkiewicz P and Darewicz M (2014) Food-Originating ACE Inhibitors, Including Antihypertensive Peptides, as Preventive Food Components in Blood Pressure Reduction, Comprehensive Reviews in Food Science and Food Safety, 10.1111/1541-4337.12051, 13:2, (114-134), Online publication date: 1-Mar-2014. Liu Y, Zhang L, Guo M, Wu H, Xie J and Wei D (2014) Virtual screening for angiotensin I-converting enzyme inhibitory peptides from Phascolosoma esculenta, Bioresources and Bioprocessing, 10.1186/s40643-014-0017-5, 1:1, Online publication date: 1-Dec-2014. Kumbhare R, Kosurkar U, Bagul P, Kanwal A, Appalanaidu K, Dadmal T and Banerjee S (2014) Synthesis and evaluation of novel triazoles and mannich bases functionalized 1,4-dihydropyridine as angiotensin converting enzyme (ACE) inhibitors, Bioorganic & Medicinal Chemistry, 10.1016/j.bmc.2014.09.027, 22:21, (5824-5830), Online publication date: 1-Nov-2014. Huang T, Mayence A and Vanden Eynde J (2014) Some non-conventional biomolecular targets for diamidines. A short survey, Bioorganic & Medicinal Chemistry, 10.1016/j.bmc.2014.02.049, 22:7, (1983-1992), Online publication date: 1-Apr-2014. Ongali B, Nicolakakis N, Tong X, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H and Hamel E (2014) Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model, Neurobiology of Disease, 10.1016/j.nbd.2014.04.018, 68, (126-136), Online publication date: 1-Aug-2014. Lau C, Abdullah N, Aminudin N and Shuib A (2013) Effect of Freeze-Drying Process on the Property of Angiotensin I-Converting Enzyme Inhibitory Peptides in Grey Oyster Mushrooms, Drying Technology, 10.1080/07373937.2013.779584, 31:13-14, (1693-1700), Online publication date: 26-Oct-2013. Tian M, Zhu D, Xie W and Shi J (2012) Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains, FEBS Letters, 10.1016/j.febslet.2012.09.004, 586:20, (3737-3745), Online publication date: 19-Oct-2012. Jankovic S and Stefanovic S (2011) Delayed angioedema during therapy with angiotensin-converting enzyme inhibitors, Vojnosanitetski pregledMilitary Medical and Pharmaceutical Journal of Serbia, 10.2298/VSP1104372J, 68:4, (372-376), . Taki M, Watanabe H, Hasegawa T, Bamba H, Shimada T and Hisa Y (2010) Angioedema: 6 years experience with fourteen cases, Auris Nasus Larynx, 10.1016/j.anl.2009.07.006, 37:2, (199-204), Online publication date: 1-Apr-2010. Sarkar P, Nicholson G and Hall G (2006) Brief review: Angiotensin converting enzyme inhibitors and angioedema: anesthetic implicationsRevue sommaire sur les implications anesthésiques de l'œdème de Quincke et des inhibiteurs de l'enzyme de conversion de l'ngiotensine, Canadian Journal of Anesthesia/Journal canadien d'anesthésie, 10.1007/BF03022528, 53:10, (994-1003), Online publication date: 1-Oct-2006. ZEYTÜNLÜOĞLU A (2019) Morchella esculanta Protein Hidrolizatlarında Anjiotensin Dönüştürücü Enzim I'in Peptid İnhibitörlerinin Araştırılması, Türk Tarım ve Doğa Bilimleri Dergisi, 10.30910/turkjans.633619, (859-869) Masarone D, Tedford R, Melillo E, Petraio A and Pacileo G (2022) Angiotensin‐converting enzyme inhibitor therapy after heart transplant: From molecular basis to clinical effects, Clinical Transplantation, 10.1111/ctr.14696 Brown D, Sheik Amamuddy O and Tastan Bishop Ö (2017) Structure-Based Analysis of Single Nucleotide Variants in the Renin-Angiotensinogen Complex, Global Heart, 10.1016/j.gheart.2017.01.006, 12:2, (121) Etchegoyen M, Nobile M, Baez F, Posesorski B, González J, Lago N, Milei J and Otero-Losada M (2018) Metabolic Syndrome and Neuroprotection, Frontiers in Neuroscience, 10.3389/fnins.2018.00196, 12 Horlock D, Kaye D, Winbanks C, Gao X, Kiriazis H, Donner D, Gregorevic P, McMullen J and Bernardo B (2021) Old Drug, New Trick: Tilorone, a Broad-Spectrum Antiviral Drug as a Potential Anti-Fibrotic Therapeutic for the Diseased Heart, Pharmaceuticals, 10.3390/ph14030263, 14:3, (263) Fuller K, McCarty C, Seaborn C, Gravlee C, Mulligan C and Moore S (2018) ACE gene haplotypes and social networks: Using a biocultural framework to investigate blood pressure variation in African Americans, PLOS ONE, 10.1371/journal.pone.0204127, 13:9, (e0204127) July 22, 2003Vol 108, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000075957.16003.07PMID: 12876137 Originally publishedJuly 22, 2003 PDF download Advertisement
Referência(s)